Genomics

Dataset Information

0

Albumin-binding RNAi Conjugate for Carrier Free Treatment of Arthritis


ABSTRACT: Osteoarthritis (OA) and rheumatoid arthritis (RA) are joint diseases that are associated with pain and lost quality of life. No disease modifying OA drugs are currently available. RA treatments are better established but are not always effective and can cause immune suppression. Here, an MMP13-selective siRNA conjugate (Albumin-binding siMMP13<(EG18L)2) was developed that, when delivered intravenously, docks onto endogenous albumin and promotes preferential accumulation in articular cartilage and synovia of post-traumatic OA (PTOA) and RA (K/BxN) joints. MMP13 expression was diminished upon intravenous delivery of MMP13 siRNA conjugates, consequently decreasing multiple histological and molecular markers of disease severity, while also reducing clinical manifestations such as swelling (RA) and joint pressure sensitivity (RA and OA). Importantly, MMP13 silencing provided more comprehensive OA treatment efficacy than standard of care (steroids) or experimental MMP inhibitors. These data demonstrate the utility of albumin ‘hitchhiking’ for drug delivery to arthritic joints, and establish the therapeutic utility of systemically delivered anti-MMP13 siRNA conjugates in OA and RA.

ORGANISM(S): Mus musculus

PROVIDER: GSE233714 | GEO | 2023/05/30

REPOSITORIES: GEO

Similar Datasets

2021-04-17 | GSE171031 | GEO
2014-02-21 | E-GEOD-55235 | biostudies-arrayexpress
2015-11-06 | E-GEOD-63106 | biostudies-arrayexpress
2014-07-28 | E-GEOD-57218 | biostudies-arrayexpress
2023-01-01 | GSE185440 | GEO
2017-07-05 | GSE100786 | GEO
2015-11-06 | GSE63106 | GEO
2011-01-13 | E-GEOD-26475 | biostudies-arrayexpress
2021-06-19 | GSE172500 | GEO
2021-12-30 | PXD027703 | Pride